The six month efficacy results of the Feasibility study of Prima Retinal Implant for patients with the dry form of age-related macular degeneration (AMD) were positive.
An electronic chip from the French company Pixium Vision, inserted under the retina to treat age-related macular degeneration, has shown
excellent results in a small clinical trial.
The company has announced positive results for its “bionic eye” used in the treatment of dry AMD. Its shares gained more than 8% on January 8 on the the Paris Stock Exchange by middle of the day.
An innovative advancement in vision restoration technology is actually
quite small. About 2×2 mm (the size of a pinhead) and as thick as a
human hair to be more precise. Called PRIMA, this bionic retinal implant system is
currently enrolling patients in a clinical trial at the University of
Pittsburgh and UPMC.